The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection.
about
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort StudyPrioritization for interferon-free regimens and potential drug interactions of current direct-acting anti-hepatitis C agents in routine clinical practice.The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug-drug interactions.Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease.Safety of oral direct acting antiviral regimens for chronic hepatitis C in real life conditions.Hepatitis C: efficacy and safety in real life.Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older.Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials.Experience and Outcomes of Hepatitis C Treatment in a Cohort of Homeless and Marginally Housed Adults.Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer.Management of drug interactions with direct-acting antivirals in Dutch HIV/hepatitis C virus-coinfected patients: adequate but not perfect.Hepatitis C Virus Clearance in Older Adults.Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt.Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments.Editorial: Direct Antiviral Agents Eliminate the Age Barrier to Treatment of Chronic Hepatitis C.
P2860
Q31168033-B6611909-C398-4737-BEDF-246B6795B970Q38606309-91F41B53-8365-48FB-9F7F-3E37D99EADF4Q38621245-FCA5BE55-EF6B-489A-AB1F-C802AE1AE063Q38741305-4D2A85FB-D051-4F94-8903-9D0D1CA7B043Q38875903-C5D2F4CB-11E4-416A-959B-C58DEB498CDEQ39040719-7EC9A819-6919-43E2-9F30-9D0BFB183D81Q39099624-F23ECE6C-3051-4E3B-856F-7206C28332A4Q39262589-93E6C400-1919-49BB-B54C-5D6A3F1A670AQ40257784-DC105F26-2540-4E03-9F5B-6771AA61D8E2Q40487793-CE326060-9A55-4ECB-A940-2CB8EF0D7E54Q45323924-8118391E-25EF-4884-BCAE-6D6C7F6784E8Q45324869-A1F16899-F3B5-489C-9CC6-6CC198CA16CEQ46445455-2FF6C1CA-F415-4FAB-98FB-3999AC805330Q47595176-CF0CDB2E-8A79-43A6-9809-D4A489A204FCQ50218917-632A80DD-C257-495B-AC1D-02AED16692A9
P2860
The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
The efficacy and safety of dir ...... c hepatitis C virus infection.
@en
type
label
The efficacy and safety of dir ...... c hepatitis C virus infection.
@en
prefLabel
The efficacy and safety of dir ...... c hepatitis C virus infection.
@en
P2093
P2860
P356
P1476
The efficacy and safety of dir ...... c hepatitis C virus infection.
@en
P2093
C Sarrazin
G Grammatikos
J Vermehren
K-H Peiffer
M-W Welker
T M Welzel
P2860
P304
P356
10.1111/APT.13769
P407
P577
2016-08-23T00:00:00Z